PAVmed Inc (NASDAQ:PAVM) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 832,500 shares, a decline of 10.3% from the January 15th total of 928,100 shares. Approximately 3.1% of the company’s shares are sold short. Based on an average trading volume of 576,000 shares, the days-to-cover ratio is currently 1.4 days.
PAVM traded up $0.60 during trading on Friday, hitting $2.46. The company’s stock had a trading volume of 4,217,800 shares, compared to its average volume of 962,655. PAVmed has a twelve month low of $0.81 and a twelve month high of $2.50. The stock’s fifty day moving average price is $1.44 and its 200-day moving average price is $1.07. The firm has a market capitalization of $56.03 million, a P/E ratio of -3.97 and a beta of 0.61.
PAVmed (NASDAQ:PAVM) last issued its quarterly earnings results on Thursday, November 21st. The company reported ($0.09) earnings per share (EPS) for the quarter.
PAVM has been the topic of a number of recent analyst reports. ValuEngine lowered PAVmed from a “hold” rating to a “sell” rating in a research note on Tuesday, February 4th. Maxim Group reissued a “buy” rating and issued a $3.00 price target on shares of PAVmed in a research note on Friday, November 22nd.
A number of institutional investors and hedge funds have recently modified their holdings of PAVM. Vanguard Group Inc. lifted its stake in PAVmed by 174.4% in the second quarter. Vanguard Group Inc. now owns 1,123,483 shares of the company’s stock valued at $1,281,000 after buying an additional 714,077 shares during the period. BlackRock Inc. acquired a new position in shares of PAVmed during the second quarter worth approximately $59,000. Levin Capital Strategies L.P. raised its position in shares of PAVmed by 500.0% during the fourth quarter. Levin Capital Strategies L.P. now owns 60,000 shares of the company’s stock worth $72,000 after purchasing an additional 50,000 shares during the period. Virtu Financial LLC acquired a new position in shares of PAVmed during the fourth quarter worth approximately $25,000. Finally, Glassman Wealth Services raised its position in shares of PAVmed by 54.9% during the third quarter. Glassman Wealth Services now owns 32,149 shares of the company’s stock worth $31,000 after purchasing an additional 11,400 shares during the period. 6.02% of the stock is currently owned by hedge funds and other institutional investors.
PAVmed Company Profile
PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube.
Featured Story: Are analyst ratings accurate?
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.